Spruce Biosciences (SPRB) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
9 Apr, 2026Executive summary
Annual meeting scheduled for May 21, 2026, at 10:00 A.M. Pacific Time, to be held virtually.
Shareholders are encouraged to review proxy materials and vote by May 20, 2026.
Voting matters and shareholder proposals
Election of three Class III directors to serve until the 2029 annual meeting.
Ratification of BDO USA, P.C. as independent auditor for fiscal year ending December 31, 2026.
Advisory vote on executive compensation (say-on-pay).
Advisory vote on the preferred frequency of future say-on-pay votes, with the board recommending annual votes.
Proxies may vote on other business as may properly come before the meeting.
Board of directors and corporate governance
Nominees for Class III director positions: Michael Grey, Camilla V. Simpson, M.Sc., and Javier Szwarcberg, M.D., MPH.
Latest events from Spruce Biosciences
- Proxy covers director elections, auditor ratification, executive pay, and governance after a 1:75 reverse split.SPRB
Proxy filing9 Apr 2026 - Lead therapy for MPS IIIB advances toward Q4 BLA submission with strong clinical and regulatory momentum.SPRB
The Citizens Life Sciences Conference 202610 Mar 2026 - FDA supports accelerated approval; commercial and financial plans are on track for launch.SPRB
Leerink Global Healthcare Conference 20269 Mar 2026 - TA-ERT program progresses toward BLA submission as net loss narrows and cash runway extends.SPRB
Q4 20259 Mar 2026 - TA-ERT is BLA-ready for MPS IIIB, with durable efficacy, safety, and strong market potential.SPRB
Corporate presentation9 Mar 2026 - TA-ERT targets MPS IIIB with durable efficacy, aiming for FDA approval and $1B+ peak sales.SPRB
Oppenheimer 36th Annual Healthcare Life Sciences Conference26 Feb 2026 - Key CAH and PCOS data readouts expected in Q3, with a depression study launching in Q4.SPRB
Jefferies Global Healthcare Conference13 Feb 2026 - Q4 data from CAH and PCOS trials will shape future strategy, with MDD and partnerships advancing.SPRB
H.C. Wainwright 26th Annual Global Investment Conference 202421 Jan 2026 - December data from key CAH studies will shape next steps for tildacerfont and future trials.SPRB
Guggenheim Inaugural Global Healthcare Innovation Conference15 Jan 2026